Connor, Clark & Lunn Investment Management Ltd. Compass Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 156,871 shares of CMPX stock, worth $454,925. This represents 0.0% of its overall portfolio holdings.
Number of Shares
156,871
Previous 232,049
32.4%
Holding current value
$454,925
Previous $426,000
46.71%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CMPX
# of Institutions
89Shares Held
93.2MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$64.9 Million0.88% of portfolio
-
Blackstone Inc New York, NY10MShares$29.1 Million0.07% of portfolio
-
Bio Impact Capital LLC Cambridge, MA8.57MShares$24.8 Million1.86% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$19.2 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.99MShares$17.4 Million0.02% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $294M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...